Dr Reddy's CEO Addresses Semaglutide Pipeline Challenges

Dr Reddy's CEO Erez Israeli anticipates strong performance in the second half of FY2026-27 once the company resolves its semaglutide supply issues, noting the highly competitive generics market for the drug.

30 Jul, 06:24 — 30 Jul, 06:24

Post Share

Sources

Showing 1 of 1 sources

bloombergHigh18d ago

Dr Reddy's CEO On Clogged Semaglutide Pipeline

Dr Reddy's CEO Erez Israeli expects a healthy performance in the second half of FY2026-27 once the company resolves the semaglutide issue. Israeli believes the generics market for semaglutide in will be ultra-competitive, with more than 20 companies trying to gain market share. (Source: Bloomberg)

Read full article →

PERSPECTA

PERSPECTA

Dr Reddy's CEO Addresses Semaglutide Pipeline Challenges

Sources

Dr Reddy's CEO On Clogged Semaglutide Pipeline

Related Stories

Paramount Seeks $1.88 Billion Bond from States in Merger Lawsuit

Tesla Prepares for Cybercab Launch in August with Employee Rides

Trump Crypto Firm Supports AI Venture with Restricted Chinese Companies

Otedola Increases First HoldCo Stake with N20.7 Billion Share Purchase

PERSPECTA